IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.

fool.com - 2026-07-07 07:40:01

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-07-06 10:40:32

Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.

fxempire.com - 2026-07-02 17:03:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-30 10:52:17

Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.

fool.com - 2026-06-23 14:40:00

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

zacks.com - 2026-06-18 11:31:04

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.

benzinga.com - 2026-06-17 12:54:55

Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop ​T-cell engaging multispecific antibodies for cancer, the ‌companies said on Wednesday.

reuters.com - 2026-06-17 07:43:56

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration DUBLIN and VANCOUVER, BC, June 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.

prnewswire.com - 2026-06-17 07:00:00

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.

prnewswire.com - 2026-06-16 16:05:00

Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.

zacks.com - 2026-06-15 13:21:09

Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca ​failed to meet the main goal of ‌improving overall survival in a late-stage study, potentially risking its current regulatory status.

reuters.com - 2026-06-12 08:53:44

For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan.

prnewswire.com - 2026-06-12 08:00:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-11 10:40:29

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities.

benzinga.com - 2026-06-10 12:44:24

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-04 12:36:30

Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.

prnewswire.com - 2026-06-04 07:45:00

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 14:12:10

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-01 10:51:18

Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting Additional subgroup analyses to be presented at the 2026 ASCO Annual Meeting show improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients For U.S. media and investors only   DUBLIN, May 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety profile of Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with and without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. The manuscript builds on the late-breaking oral presentation of the HERIZON-GEA-01 trial results at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI), where zanidatamab-containing combinations demonstrated unprecedented progression-free survival (PFS) and overall survival (OS) outcomes in a global Phase 3 trial.

prnewswire.com - 2026-05-27 17:00:00

Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript

seekingalpha.com - 2026-05-27 16:27:10

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-26 10:40:24

One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying.

247wallst.com - 2026-05-19 12:24:55

Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-19 10:51:01

Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

247wallst.com - 2026-05-19 08:04:37

JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.

zacks.com - 2026-05-13 09:00:49

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m.

prnewswire.com - 2026-05-12 16:15:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-12 10:51:13

Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

zacks.com - 2026-05-11 10:16:29

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-08 10:40:27

Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving double-digit sales growth and diversifying away from legacy neuroscience revenues. Ziihera's Priority Review for HER2+ GEA and multiple late-stage trials position JAZZ for significant market expansion and $2B+ peak sales potential via a HER2+ 'pipeline-in-a-product.'

seekingalpha.com - 2026-05-06 16:21:44

Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.

zacks.com - 2026-05-06 11:32:10

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 02:51:14

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-05-05 21:31:32

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.34 per share, beating the Zacks Consensus Estimate of $4.67 per share. This compares to earnings of $1.68 per share a year ago.

zacks.com - 2026-05-05 19:05:26

– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav® revenues grew 18% YoY with 425 net patient adds – – Epidiolex® revenues grew 15% YoY– – Company reaffirms 2026 revenue and expense guidance – DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

prnewswire.com - 2026-05-05 16:05:00

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:07:42

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) containing combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date of August 25, 2026.

prnewswire.com - 2026-04-27 07:45:00

DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

prnewswire.com - 2026-04-21 16:15:00

Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in HER2+ GEA For U.S. media and investors only DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-June 2, 2026, in Chicago. The data reflect Jazz's continued momentum in oncology and the Company's focus on advancing treatment approaches in difficult-to-treat cancers through late-stage clinical research, real-world evidence and ongoing pipeline innovation.

prnewswire.com - 2026-04-21 16:05:00

Assetmark Inc. grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 102.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,848 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,499 shares during the period. Assetmark Inc.'s holdings in Jazz

defenseworld.net - 2026-04-21 03:24:52

Choreo LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund bought 2,883 shares of the specialty pharmaceutical company's stock, valued at approximately $492,000. Several other institutional investors also recently made changes to their

defenseworld.net - 2026-04-19 04:36:58

KBC Group NV boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 7.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 103,338 shares of the specialty pharmaceutical company's stock after buying an additional 7,055 shares during the quarter. KBC

defenseworld.net - 2026-04-18 04:13:08

Jazz Pharmaceuticals (NASDAQ: JAZZ) executives highlighted record 2025 revenue, a growing pipeline anchored by oncology programs, and a refined strategy emphasizing rare diseases during a conference session featuring Chief Financial Officer Philip Johnson and investor relations leaders Jack Spinks and John Bluth. 2025 results and 2026 outlook Johnson said 2025 marked "our 21st consecutive year of

defenseworld.net - 2026-04-18 01:05:18

Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

seekingalpha.com - 2026-04-15 16:11:45